Creative Biolabs Announces Its Advances in Chemical Conjugate Development

 Breaking News
  • No posts were found

Creative Biolabs Announces Its Advances in Chemical Conjugate Development

May 23
23:43 2023
Creative Biolabs, a leading CRO company specializing in molecule drug discoveries, has made significant progress in drug designs of chemical conjugates, such as antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs).

New York, USA – May 23, 2023 – Both ADCs and PROTACs can be classified as conjugates due to their similar chemical structures, which incorporate a linker to connect different components. “We’ve established comprehensive PROTAC design services and a one-stop ADC development platform for researchers to fuel the advancement in these two popular therapeutic routes that have brought new hope to cancer treatment,” said a scientist of Creative Biolabs.

The efficacy of protac in degrading pathogenic proteins is influenced by three parts in its structure: the target protein binding domain, the ligand used to recruit the degradation mechanism, and the chemical linker. The PROTACT platform, offered by Creative Biolabs, accommodates various customize services about the linker and two ligands to meet different requirements.

The ligand design services cover all aspects of the target protein, including cytoplasmic, nuclear, and transmembrane targets. For the target protein of interest classified as a reported transcription factor, non-enzyme protein, scaffold protein, kinase, receptor, or bromodomain, the corresponding ligand products can be developed upon request.

The platform also supports ligand screening for E3 ligase, where the most popular E3 ligases include the von Hippel-Lindau disease tumor suppressor protein (VHL), the mouse double minute 2 homologue (MDM2), the cellular inhibitor of apoptosis (cIAP), and cereblon (CRBN).

The protac linker design and optimization services offered by Creative Biolabs feature optimizing the length and position of the linker to achieve maximum interaction between the target protein and E3 ligase.

“Besides protacs, antibody-drug conjugates’ high degree of specificity and affinity for specific targets making them evergreens among the emerging therapeutic approaches,” the scientist continued.

Creative Biolabs’ one-stop ADC development platform applies ADC biotechnology in six independent but interconnected modules ranging from antibody identification and screening to ADC evaluation, such as drug linker customization, antibody design and conjugation, and in vitro analysis of ADCs.

Specifically, the chemical design of a chemically compatible antibody for conjugation is a critical step that directly determines the fate of an ADC project. During antibody design and engineering, Creative Biolabs introduces a series of chemically binding sites into the antibody sequence. Additionally, several enzymatic or physical methods are applied to antibody conjugation to provide site-specific antibody-drug conjugation.

For more detailed services about PROTACs and ADCs, please visit

About Creative Biolabs

Creative Biolabs specializes in providing advanced and customized services to accelerate the discovery and development of antibody-drug conjugates and proteolysis-targeting chimeras. The comprehensive solutions of drug development provided by Creative Biolabs span from target identification to preclinical assessment to satisfy the various requirements of global clients.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States

Related Articles